Headquartered in South San Francisco, California, Talon Therapeutics (TLON.OB)(fka Hana Biosciences) is a publicly traded biopharmaceutical company focused on developing and commercializing novel treatments in oncology. Its lead drug, Marqibo, is a novel formulation of the widely used cancer drug Vincristine. Talon has completed a pivotal clinical trial with Marqibo in adults with Acute Lymphoblastic Leukemia ("ALL"), and the Company plans to file for Food and Drug Administration ("FDA") approval in this indication. One of Talon's other key development programs, Menadione, is completing Phase I studies for treatment of the serious skin toxicity caused by a major class of approved cancer drugs.
In June 2010, Warburg Pincus led a preferred stock financing of Talon, which gave Warburg Pincus the right to appoint majority of the board. Warburg Pincus has recruited Robert Spiegel, Ph.D., former Chief Medical Officer and Senior Vice President of Worldwide Clinical Research of Schering Plough, to Talon’s board.
Back to Previous Page